Summary
Thymalin is a peptide mixture extracted from calf thymus, the gland where immune T cells mature, that has been registered as an immunomodulating (immune adjusting) drug in Russia since the 1980s. Russian reports describe restored T cell counts and, in the developer's long term follow up of elderly patients, lower mortality, but these studies are open and non-randomized (no chance assignment to a comparison group), come mostly from one institute, and are not independently replicated. It has never been reviewed or approved by FDA, is not on the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), and is not available through licensed channels in the United States.
What is Thymalin?
Thymalin is a polypeptide extract from calf thymus (a mixture of low molecular weight peptides), registered as a drug in Russia. It is also known as Thymalinum, Thymus extract peptide complex, Timalin, Glu-Trp dipeptide (thymogen) is its synthetic derivative.
How does it work?
Thymalin contains short thymic peptides, including the dipeptide Glu-Trp, that are proposed to promote differentiation and maturation of T lymphocytes and to normalize the ratio of helper to suppressor T cells. In vitro, thymalin activated differentiation of human hematopoietic stem cells and altered expression of genes involved in immune signaling in cell lines. Mechanisms come from cell studies and Russian clinical reports rather than controlled pharmacology.
| Cluster | Longevity and mitochondrial |
|---|---|
| Routes | Intramuscular injection (Russian labeling and reports); Subcutaneous injection (as sold) |
| Conditions studied | Inflammation and inflammatory bowel disease; Longevity and healthy aging; Immune support and immune deficiency |
| Record | v3, draft, verified Sep 22, 2026 |
What does the evidence say about Thymalin?
Human evidence is limited to non-randomized studies. Khavinson and Morozov (2003) reported that elderly patients given courses of Thymalin, with or without the pineal preparation Epithalamin, over 6 to 12 years had lower mortality and fewer infections and cardiovascular events than untreated controls; the study was open, not randomized, and from the developing institute. Khavinson et al. (2021) reported a small open study in which thymalin added to standard care in hospitalized COVID-19 patients was associated with faster normalization of inflammatory markers. In vitro work (2020) showed activation of hematopoietic stem cell differentiation. No randomized controlled trial or independent replication has been indexed.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 0 | n/a |
| Human observational studies | 2 | n/a |
| Animal studies | 1 | n/a |
| All indexed studies | 3 | n/a |
Human evidence
Khavinson 2003: open, non-randomized long term follow up of elderly patients in St. Petersburg treated with Thymalin and Epithalamin courses; authors report reduced mortality over 6 to 12 years and fewer acute respiratory infections. Khavinson 2021: open comparative study of thymalin added to standard therapy in COVID-19 patients, reporting faster reduction of C-reactive protein and lymphocyte recovery; small, not randomized or blinded. No pharmacokinetic or dose ranging study has been published in English.
Animal evidence
Rodent and cell studies from the same group report restoration of immune function after thymectomy, radiation, or aging and stimulation of T cell differentiation. Khavinson 2020 showed thymalin activated differentiation of human hematopoietic stem cells in culture. Independent animal work is scarce.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Peptides of pineal gland and thymus prolong human life2003 PMID 14523363 | Open, non-randomized long term follow up of elderly patients treated with thymus and pineal peptide preparationsElderly patients in Russia treated with Thymalin and Epithalamin | Authors report lower mortality and fewer infections and cardiovascular events over 6 to 12 years versus untreated controls; not randomized and from the developing institute | Evidence: Human observational evidence |
| Thymalin: activation of differentiation of human hematopoietic stem cells2020 PMID 33237528 | In vitro studyCultured human hematopoietic stem cells | Thymalin increased expression of differentiation markers in cultured hematopoietic stem cells | Evidence: Animal-only evidence |
| Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-192021 PMID 33575961 | Open comparative clinical studyHospitalized adults with COVID-19 receiving standard therapy with or without thymalin | Faster normalization of inflammatory markers and lymphocyte counts reported in the thymalin group; small, not randomized or blinded | Evidence: Human observational evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Inflammation and inflammatory bowel disease | Not graded | KPV, thymosin alpha-1, LL-37, VIP, and BPC-157 are marketed as anti-inflammatory peptides. Thymosin alpha-1 has human trials in hepatitis and sepsis outside the United States. KPV has rodent colitis data only. VIP analogs have been studied in small human trials for sarcoidosis and pulmonary hypertension. |
| Longevity and healthy aging | Not graded | No peptide has been shown to extend human lifespan. MOTS-c, humanin, and SS-31 (elamipretide) are mitochondrial peptides with rodent data and, for elamipretide, human trials in mitochondrial myopathy and Barth syndrome. Epitalon and FOXO4-DRI rest on animal or in vitro data. GLP-1 agonists have the strongest human outcome data for mortality relevant endpoints, through cardiovascular risk reduction. |
| Immune support and immune deficiency | Evidence: Human observational evidence | Uncontrolled Russian reports of faster lymphocyte and inflammatory marker recovery, including in hospitalized COVID-19 patients; not approved outside Russia. |
Is Thymalin legal in the United States?
FDA and compounding status
Thymalin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. As an animal tissue extract of undefined composition it is not a candidate for 503A bulk compounding, and it is not eligible for 503B outsourcing. It is registered as a prescription drug in Russia and some neighboring countries. Products sold in the United States under this name are not lawful for human use.
WADA status
WADA status unclear. The current prohibited list does not name this compound explicitly and its class status is not settled. Athletes should ask their anti-doping organization before use.
Regulatory timeline
No regulatory events recorded.
What published studies of Thymalin used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in indexed human literature. Russian labeling describes intramuscular courses, but no dose finding trial has been published in an indexed journal, so no dose range is reported here.
Routes reported
| # | Route |
|---|---|
| 1 | Intramuscular injection (Russian labeling and reports) |
| 2 | Subcutaneous injection (as sold) |
What are the side effects and interactions of Thymalin?
Side effects
| # | Reported side effect |
|---|---|
| 1 | No systematic safety data from randomized trials |
| 2 | Allergic reactions are the main risk listed for a bovine tissue extract |
| 3 | Injection site pain |
| 4 | Theoretical prion and adventitious agent risk with unverified bovine thymus products of unknown origin |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal interaction studies exist |
| 2 | Theoretical opposition to immunosuppressants (corticosteroids, calcineurin inhibitors, biologics) given proposed immune stimulating action (not tested) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Known hypersensitivity to bovine proteins |
| 2 | Autoimmune disease or organ transplant (theoretical immune stimulation) |
| 3 | Pregnancy and breastfeeding (no data) |
| 4 | Competitive athletes should confirm status with their anti-doping organization |
How do people access Thymalin legally?
Typical cost: Not available through licensed US channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Verified access options
Step 1
Not legally available in the United States: no approved product and no 503A bulks listing.
Step 2
Prescription drug in Russia and some neighboring countries.
Step 3
Products labeled research use only are not lawful for human use and are not verified for identity or purity.
Access paths are verified against public regulatory records and prescriber licensing. We never list unlicensed vendors.
Compare Thymalin
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. That does not make thymalin lawful. Thymalin is not FDA approved and not on the 503A bulks list, so a pharmacy has no lawful basis to compound it. [4] [7]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [7] [8] [9] [10] [11]
What changes for you
- No FDA review of the product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [11]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [7]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, WADA status is unclear; ask your anti-doping organization before any use. [6]
What to check
These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [11]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Frequently asked questions
Is thymalin legal in the United States?
It is not an FDA approved drug and is not on the FDA 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), so no US compounding pharmacy can lawfully make it. Possessing it is not a crime, but the only products on the US market are research chemicals that are not lawful for human use. It is a registered prescription drug in Russia. [4] [5]
Does thymalin work to boost the immune system?
Russian open label reports describe restored T cell counts and fewer infections, and an in vitro study showed it activated differentiation of human blood stem cells. But no randomized, blinded trial has been published and the human data come almost entirely from one institute, so the effect size in people is unknown. PeptideAgent grades the evidence human observational. [1] [2] [3]
Does thymalin extend lifespan?
The claim comes from a 2003 report in which elderly patients given Thymalin and Epithalamin courses had lower mortality over 6 to 12 years than untreated controls. That study was not randomized, participants were not blinded, and it has not been replicated independently, so it cannot establish that thymalin prolongs life. [1]
What are the side effects of thymalin?
No randomized safety data exist. As a bovine thymus extract, allergic reactions are the main labeled risk, along with injection site pain. Unverified products carry the additional concern of contamination or animal derived infectious agents, since the source and processing cannot be checked. [3]
How is thymalin taken?
Not established in indexed human literature. Russian labeling describes intramuscular courses given as short repeated cycles, but no dose finding trial has been published in an indexed journal, so PeptideAgent does not report a regimen. [1] [3]
Is thymalin banned by WADA?
Unclear. Thymalin is not named on the WADA Prohibited List, and because it is an approved drug in Russia it does not fall automatically under section S0 for non-approved substances. However, its composition is undefined and immune modulators can be reviewed case by case, so athletes should check with their anti-doping organization before use. [6]
Thymalin vs thymosin alpha-1: what is the difference?
Thymosin alpha-1 is a single defined 28 amino acid peptide that has been approved in several countries and studied in randomized trials for hepatitis B and as a vaccine adjuvant. Thymalin is an undefined mixture of thymus peptides with only non-randomized Russian data. Neither is FDA approved, but thymosin alpha-1 has a far larger and more rigorous evidence base. [1] [2]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Thymosin alpha-1 access: approved abroad, not in the US
Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and US compounding has no lawful basis. What that means for access, forms, and thymalin.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003PubMed 14523363, 2003
- [2]Khavinson VK et al. Thymalin: activation of differentiation of human hematopoietic stem cells. Bull Exp Biol Med 2020PubMed 33237528, 2020
- [3]Khavinson VK et al. Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-19. Stem Cell Rev Rep 2021PubMed 33575961, 2021
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [5]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [6]WADA Prohibited ListWADA, 2026
- [7]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2)FDA
- [8]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
- [9]FDA warning letters database: July 30, 2019 letter to a 503A pharmacy that compounded BPC-157 acetate outside section 503AFDA, 2019
- [10]FDA Import Alert 66-41: Detention without physical examination of unapproved new drugs promoted in the U.S. (includes peptide entries)FDA
- [11]FDA: Compounding and the FDA, questions and answersFDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). Thymalin: evidence, legality, and access. https://peptideagent.ai/peptides/thymalin- HTML link
<a href="https://peptideagent.ai/peptides/thymalin">Thymalin: evidence, legality, and access</a>, PeptideAgent, updated September 22, 2026.